Kyntra Bio, Inc. Common Stock — Graphique, cours et actualités (NASDAQ:KYNB)

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Market Capitalization 28.05 M
Employee 34
Founded 1993
CEO N/A
Website www.kyntrabio.com
Headquarter California, United States
FIGI BBG000FW5ZL6
Industry Biotechnologies

Chiffre d'affaires total

Résultat net

Bénéfice par action de base (BPA de base)

Dette totale

Flux de trésorerie disponible

Trésorerie et équivalents de trésorerie

Kyntra Bio, Inc. - Common Stock

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.